Kinetic Analysis of Hepatotoxicity Associated with Antineoplastic Asparaginases

Donald L Durden, Ana M. Salazar, John A. Distasio

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

In early studies using high dosages of Escherichia coli asparaginase (10 doses of 1000 IU/kg each) for the treatment of acute lymphoblastic leukemia, hepatotoxicity was a major complication of therapy. Biochemical evidence of hepatic dysfunction occurred in 75% of patients during the first 2 weeks of treatment. Currently, the use of lower dosages of E. coli asparaginase (three doses of 6000 IU/sq m each) has reduced the incidence of hepatic complication. Hepatic dysfunction in the form of severe life-threatening thromboembolic coagulopathy, however, continues to be associated with the use of this enzyme. Our previous work has established that the fatty degenerative changes and hepatocellular dysfunction associated with short-term (1 week) E. coli asparaginase treatment does not occur in mice treated with a glutaminase-free asparaginase from Vibrio succinogenes. In this report, we examined the hepatotoxic effects of prolonged treatment with E. coli and Erwinia carotovora asparaginases and compared the observed toxicities to those observed with the glutaminase-free asparaginase from V. succinogenes. Using a murine model, our data indicate that the hepatotoxicity of E. coli asparaginase parallels the toxicity observed in humans with a rapid increase in liver lipid levels and decreased plasma levels of albumin, antithrombin III, cholesterol, and triglycerides occurring in the first and second weeks followed by a resumption to normal hepatic function during Weeks 3 and 4. In contrast, prolonged treatment of mice with V. succinogenes asparaginase is not associated with significant hepatotoxicity. Er. carotovora asparaginase treatment is associated with an intermediate level of toxicity as indicated by increased hepatic lipid concentration occurring during the second and fourth weeks of treatment. Hepatic function as determined by plasma lipids and proteins was normal in Er. carotovora asparaginase-treated mice. Our data suggest that the combined physiological depletion of asparagine and glutamine following administration of E. coli or Er. carotovora asparaginases may result in pronounced hepatotoxicity. In contrast, a glutaminase-free asparaginase with potent antilymphoma activity isolated from V. succinogenes is not hepatotoxic even after prolonged treatment. Therefore, it may prove to be a more efficacious antitumor agent in humans.

Original languageEnglish (US)
Pages (from-to)1602-1605
Number of pages4
JournalCancer Research
Volume43
Issue number4
StatePublished - Apr 1 1983

Fingerprint

Asparaginase
Antineoplastic Agents
Pectobacterium carotovorum
Escherichia coli
Liver
Therapeutics
Lipids
Vibrio
Antithrombin III
Asparagine
Glutamine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Serum Albumin
Blood Proteins
Triglycerides
Cholesterol

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kinetic Analysis of Hepatotoxicity Associated with Antineoplastic Asparaginases. / Durden, Donald L; Salazar, Ana M.; Distasio, John A.

In: Cancer Research, Vol. 43, No. 4, 01.04.1983, p. 1602-1605.

Research output: Contribution to journalArticle

Durden, DL, Salazar, AM & Distasio, JA 1983, 'Kinetic Analysis of Hepatotoxicity Associated with Antineoplastic Asparaginases', Cancer Research, vol. 43, no. 4, pp. 1602-1605.
Durden, Donald L ; Salazar, Ana M. ; Distasio, John A. / Kinetic Analysis of Hepatotoxicity Associated with Antineoplastic Asparaginases. In: Cancer Research. 1983 ; Vol. 43, No. 4. pp. 1602-1605.
@article{7ef00510b7074a9ba1e16d6f6e630e33,
title = "Kinetic Analysis of Hepatotoxicity Associated with Antineoplastic Asparaginases",
abstract = "In early studies using high dosages of Escherichia coli asparaginase (10 doses of 1000 IU/kg each) for the treatment of acute lymphoblastic leukemia, hepatotoxicity was a major complication of therapy. Biochemical evidence of hepatic dysfunction occurred in 75{\%} of patients during the first 2 weeks of treatment. Currently, the use of lower dosages of E. coli asparaginase (three doses of 6000 IU/sq m each) has reduced the incidence of hepatic complication. Hepatic dysfunction in the form of severe life-threatening thromboembolic coagulopathy, however, continues to be associated with the use of this enzyme. Our previous work has established that the fatty degenerative changes and hepatocellular dysfunction associated with short-term (1 week) E. coli asparaginase treatment does not occur in mice treated with a glutaminase-free asparaginase from Vibrio succinogenes. In this report, we examined the hepatotoxic effects of prolonged treatment with E. coli and Erwinia carotovora asparaginases and compared the observed toxicities to those observed with the glutaminase-free asparaginase from V. succinogenes. Using a murine model, our data indicate that the hepatotoxicity of E. coli asparaginase parallels the toxicity observed in humans with a rapid increase in liver lipid levels and decreased plasma levels of albumin, antithrombin III, cholesterol, and triglycerides occurring in the first and second weeks followed by a resumption to normal hepatic function during Weeks 3 and 4. In contrast, prolonged treatment of mice with V. succinogenes asparaginase is not associated with significant hepatotoxicity. Er. carotovora asparaginase treatment is associated with an intermediate level of toxicity as indicated by increased hepatic lipid concentration occurring during the second and fourth weeks of treatment. Hepatic function as determined by plasma lipids and proteins was normal in Er. carotovora asparaginase-treated mice. Our data suggest that the combined physiological depletion of asparagine and glutamine following administration of E. coli or Er. carotovora asparaginases may result in pronounced hepatotoxicity. In contrast, a glutaminase-free asparaginase with potent antilymphoma activity isolated from V. succinogenes is not hepatotoxic even after prolonged treatment. Therefore, it may prove to be a more efficacious antitumor agent in humans.",
author = "Durden, {Donald L} and Salazar, {Ana M.} and Distasio, {John A.}",
year = "1983",
month = "4",
day = "1",
language = "English (US)",
volume = "43",
pages = "1602--1605",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Kinetic Analysis of Hepatotoxicity Associated with Antineoplastic Asparaginases

AU - Durden, Donald L

AU - Salazar, Ana M.

AU - Distasio, John A.

PY - 1983/4/1

Y1 - 1983/4/1

N2 - In early studies using high dosages of Escherichia coli asparaginase (10 doses of 1000 IU/kg each) for the treatment of acute lymphoblastic leukemia, hepatotoxicity was a major complication of therapy. Biochemical evidence of hepatic dysfunction occurred in 75% of patients during the first 2 weeks of treatment. Currently, the use of lower dosages of E. coli asparaginase (three doses of 6000 IU/sq m each) has reduced the incidence of hepatic complication. Hepatic dysfunction in the form of severe life-threatening thromboembolic coagulopathy, however, continues to be associated with the use of this enzyme. Our previous work has established that the fatty degenerative changes and hepatocellular dysfunction associated with short-term (1 week) E. coli asparaginase treatment does not occur in mice treated with a glutaminase-free asparaginase from Vibrio succinogenes. In this report, we examined the hepatotoxic effects of prolonged treatment with E. coli and Erwinia carotovora asparaginases and compared the observed toxicities to those observed with the glutaminase-free asparaginase from V. succinogenes. Using a murine model, our data indicate that the hepatotoxicity of E. coli asparaginase parallels the toxicity observed in humans with a rapid increase in liver lipid levels and decreased plasma levels of albumin, antithrombin III, cholesterol, and triglycerides occurring in the first and second weeks followed by a resumption to normal hepatic function during Weeks 3 and 4. In contrast, prolonged treatment of mice with V. succinogenes asparaginase is not associated with significant hepatotoxicity. Er. carotovora asparaginase treatment is associated with an intermediate level of toxicity as indicated by increased hepatic lipid concentration occurring during the second and fourth weeks of treatment. Hepatic function as determined by plasma lipids and proteins was normal in Er. carotovora asparaginase-treated mice. Our data suggest that the combined physiological depletion of asparagine and glutamine following administration of E. coli or Er. carotovora asparaginases may result in pronounced hepatotoxicity. In contrast, a glutaminase-free asparaginase with potent antilymphoma activity isolated from V. succinogenes is not hepatotoxic even after prolonged treatment. Therefore, it may prove to be a more efficacious antitumor agent in humans.

AB - In early studies using high dosages of Escherichia coli asparaginase (10 doses of 1000 IU/kg each) for the treatment of acute lymphoblastic leukemia, hepatotoxicity was a major complication of therapy. Biochemical evidence of hepatic dysfunction occurred in 75% of patients during the first 2 weeks of treatment. Currently, the use of lower dosages of E. coli asparaginase (three doses of 6000 IU/sq m each) has reduced the incidence of hepatic complication. Hepatic dysfunction in the form of severe life-threatening thromboembolic coagulopathy, however, continues to be associated with the use of this enzyme. Our previous work has established that the fatty degenerative changes and hepatocellular dysfunction associated with short-term (1 week) E. coli asparaginase treatment does not occur in mice treated with a glutaminase-free asparaginase from Vibrio succinogenes. In this report, we examined the hepatotoxic effects of prolonged treatment with E. coli and Erwinia carotovora asparaginases and compared the observed toxicities to those observed with the glutaminase-free asparaginase from V. succinogenes. Using a murine model, our data indicate that the hepatotoxicity of E. coli asparaginase parallels the toxicity observed in humans with a rapid increase in liver lipid levels and decreased plasma levels of albumin, antithrombin III, cholesterol, and triglycerides occurring in the first and second weeks followed by a resumption to normal hepatic function during Weeks 3 and 4. In contrast, prolonged treatment of mice with V. succinogenes asparaginase is not associated with significant hepatotoxicity. Er. carotovora asparaginase treatment is associated with an intermediate level of toxicity as indicated by increased hepatic lipid concentration occurring during the second and fourth weeks of treatment. Hepatic function as determined by plasma lipids and proteins was normal in Er. carotovora asparaginase-treated mice. Our data suggest that the combined physiological depletion of asparagine and glutamine following administration of E. coli or Er. carotovora asparaginases may result in pronounced hepatotoxicity. In contrast, a glutaminase-free asparaginase with potent antilymphoma activity isolated from V. succinogenes is not hepatotoxic even after prolonged treatment. Therefore, it may prove to be a more efficacious antitumor agent in humans.

UR - http://www.scopus.com/inward/record.url?scp=0020538536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020538536&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 1602

EP - 1605

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -